SCHEMBL6315938

SCHEMBL6315938

COc1ccc(-c2noc(N)c2C(=O)NC(c2ccccc2)c2ccccc2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.45
MAPK1 P28482 1/20 0.44
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 2/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
ATR Q13535 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
S1PR3 Q99500 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
HPGDS O60760 1/20 0.38
GABRA5 P31644 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321552 0.91 MAPK1 (0.52) GABRA1MAPK1RAB9ALMNAALDH1A1
SCHEMBL6314761 0.87 GABRA5 (0.44) GABRA1MAPK1RAB9ALMNACYP3A4
SCHEMBL6323447 0.84 EPHX2 (0.45) GABRA1MAPK1RAB9ALMNAALDH1A1
SCHEMBL6317173 0.84 GABRA1 (0.49) GABRA1MAPK1RAB9ALMNAPOLB
SCHEMBL6316655 0.83 GABRA1 (0.49) GABRA1MAPK1RAB9ALMNAMKNK1
SCHEMBL6618320 0.83 RIPK1 (0.45) GABRA1MAPK1RAB9ALMNAPOLB
SCHEMBL6323876 0.83 CNR1 (0.46) GABRA1LMNAALDH1A1KMT2APOLB
SCHEMBL6323390 0.82 GABRA1 (0.50) GABRA1MAPK1RAB9ALMNATP53
SCHEMBL6318899 0.82 GABRA1 (0.49) GABRA1MAPK1RAB9ALMNAALDH1A1
SCHEMBL6322798 0.82 GABRA1 (0.49) GABRA1MAPK1RAB9ALMNAMKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GABRA1 886/4885MAPK1 178/4885RAB9A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.